You are here

  • Home
  • Archive
  • Volume 32, Issue 6
  • Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Article info

Article menu
Original research
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Authors

  • Yeh Chen Lee Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, AustraliaUniversity of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, AustraliaPrince of Wales Clinical School, Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Madeleine T King University of Sydney, Quality of Life Office of Psycho-Oncology Research Group (PoCoG), Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Rachel L O'Connell University of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Anne Lanceley UCL Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, UK PubMed articlesGoogle scholar articles
  • Florence Joly GINECO-Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris, FranceOncology, Ctr Francois Baclesse, Caen, France PubMed articlesGoogle scholar articles
  • Felix Hilpert Arbeitsgesmeinschaft Gynäkologische Onkologie Studiengruppe (AGO) und North-Eastern German Society of Gynecologcial Oncology (NOGGO), Kiel, GermanyOnkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Alison Davis Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, AustraliaMedical Oncology, Canberra Hospital, Canberra, Australian Capital Territory, Australia PubMed articlesGoogle scholar articles
  • Felicia T Roncolato Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, AustraliaUniversity of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Aikou Okamoto Japanese Gynecologic Oncology Group (JGOG), Tokyo, JapanDepartment of Obstetrics and Gynecology, Jikei University School of Medicine, Minato-ku, Japan PubMed articlesGoogle scholar articles
  • Jane Bryce Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, ItalyAscension St John Clinical Research Institute, Tulsa, Oklahoma, USAMITO Multicentre Italian Trials in Ovarian and gynecologic cancer, Italy PubMed articlesGoogle scholar articles
  • Paul Donnellan Cancer Trials Ireland, Galway University Hospital, Galway, Ireland PubMed articlesGoogle scholar articles
  • Amit M Oza Princess Margaret Consortium (PMHC), Toronto, Ontario, CanadaPrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Elisabeth Avall-Lundqvist Nordic Society of Gynaecological Oncology (NSGO), Copenhagen, DenmarkDepartment of Oncology and Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, SwedenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Jonathan S Berek Cooperative Gynecologic Oncology Investigators (COGI), Stanford, California, USAStanford Women's Cancer Centre, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA PubMed articlesGoogle scholar articles
  • Jonathan A Ledermann The Cancer Research UK and UCL Cancer Trials Centre, NCRI UK, London, UK PubMed articlesGoogle scholar articles
  • Dominique Berton GINECO-Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris, FranceInstitut de Cancérologie de l’Ouest, Centre René Gauducheau, Saint Herblain, France PubMed articlesGoogle scholar articles
  • Jalid Sehouli Arbeitsgesmeinschaft Gynäkologische Onkologie Studiengruppe (AGO) und North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, GermanyDepartment of Gynecology and Oncological Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Amanda Feeney The Cancer Research UK and UCL Cancer Trials Centre, NCRI UK, London, UK PubMed articlesGoogle scholar articles
  • Marie-Christine Kaminsky GINECO-Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Paris, FranceInstitut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France PubMed articlesGoogle scholar articles
  • Katrina Diamante University of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Martin R Stockler University of Sydney, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Michael L Friedlander Australia New Zealand Gynaecological Oncology Group (ANZGOG), Camperdown, New South Wales, AustraliaPrince of Wales Clinical School, Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia PubMed articlesGoogle scholar articles
  • for the GCIG Symptom Benefit Group
    Google scholar articles
  1. Correspondence to Professor Michael L Friedlander, Prince of Wales Hospital, Barker Street, Randwick, New South Wales 2031, Australia; m.friedlander{at}unsw.edu.au
View Full Text

Citation

Lee YC, King MT, O'Connell RL for the GCIG Symptom Benefit Group, et al
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
International Journal of Gynecologic Cancer 2022;32:761-768.

Publication history

  • Received September 26, 2021
  • Accepted January 7, 2022
  • First published January 27, 2022.
Online issue publication 
May 18, 2023

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.